NCT05771103

Stellate Ganglion Destruction With Alcohol Versus Thermal Ablation for Chronic Post Mastectomy Pain

Status unknown NA Last updated 2 August 2023

What this trial tests

NA trial testing thermal Radiofrequency neurolysis of Stellate ganglion in Post-mastectomy Pain Syndrome in 70 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
30 July 2023

30 July 2023

Quick facts

Lead sponsor	National Cancer Institute, Egypt
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	70
Start date	1 January 2023
Primary completion	30 July 2023
Estimated completion	30 July 2023
Sites	1 location across Egypt

Drugs / interventions tested

• thermal Radiofrequency neurolysis of Stellate ganglion

Conditions studied

• Post-mastectomy Pain Syndrome — all drugs for Post-mastectomy Pain Syndrome →

Sponsor

National Cancer Institute, Egypt

Who can join

Adults 20 to 65, female only, with Post-mastectomy Pain Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

* Group A: SGB with alcohol injection by ultrasound guidance and C7 level confirmation by fluoroscopy.
* Group B: Thermal RF; thermal RF neurolysis will be applied with a time of 60 seconds at 80º C, and then will be repeated twice . Stellate ganglion RF therapy will be done under fluoroscopy, integrated by ultrasound guidance

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Emerging advances in drug delivery systems (DDSs) for optimizing cancer complications.
   Li K, Guo B, Gu J, Ta N, et al · · 2025 · cited 8× · PMID 39759851 · DOI 10.1016/j.mtbio.2024.101375